PROTAC ER Degraders in ER+/HER2- MBC Progressing After Endocrine Therapy: Emerging Mechanisms and Implications for Clinical Practice on the Horizon

Learn more about the emerging evidence of PROTAC ER degraders to treat estrogen receptor–positive/HER2-negative metastatic breast cancer, including mechanisms of action and how these novel therapies compare to standard-of-care endocrine therapies. 

Share

Program Content

Activities

PROTACs in ER+/HER2- MBC
PROTAC ER Degraders in ER+/HER2- MBC Progressing After Endocrine Therapy: Current Treatment Landscape and Unmet Needs for Patients
Video
Congratulations: You achieved a completion on 04/09/2022

Released: November 19, 2024

Expires: April 18, 2025

PROTACs: Data in ER+/HER2- MBC
PROTAC ER Degraders in ER+/HER2- MBC After ET: Novel ER-Targeting Therapy Data and a Look to the Future
Video
Congratulations: You achieved a completion on 04/09/2022

Released: November 14, 2024

Expires: April 13, 2025

Activities

PROTACs in ER+/HER2- MBC
PROTAC ER Degraders in ER+/HER2- MBC Progressing After Endocrine Therapy: Current Treatment Landscape and Unmet Needs for Patients
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: November 19, 2024

Expires: November 18, 2025

PROTACs: Data in ER+/HER2- MBC
PROTAC ER Degraders in ER+/HER2- MBC After ET: Novel ER-Targeting Therapy Data and a Look to the Future 
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: November 19, 2024

Expires: November 18, 2025

Faculty

cover img faculity

Erika P. Hamilton, MD

Director, Breast Cancer Research Program
Chair, Breast Executive Committee
Sarah Cannon Research Institute
Nashville, Tennessee

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC

Supporters

Supported by an educational grant from Pfizer Inc.

Pfizer Inc.